Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 123 results:
Συντάκτης Τίτλος Τύπος [ Έτος(Asc)]
Φίλτρα: Συντάκτης is Tsapas, Apostolos  [Clear All Filters]
2018
Bekiari, E., Kitsios K., Thabit H., Tauschmann M., Athanasiadou E., Karagiannis T., et al. (2018).  Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis.. BMJ. 361, k1310.
Gourzoulidis, G., Tzanetakos C., Ioannidis I., Tsapas A., Kourlaba G., Papageorgiou G., et al. (2018).  Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece. Clinical Drug Investigation. 3831184061314132015410373121437191919154637191436(511Suppl 2518942221193773988), 417 - 426.
Gourzoulidis, G., Tzanetakos C., Ioannidis I., Tsapas A., Kourlaba G., Papageorgiou G., et al. (2018).  Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece.. Clin Drug Investig. 38(5), 417-426.
Bekiari, E., Karagiannis T., & Tsapas A. (2018).  In type 2 diabetes, weekly semaglutide reduced HbA 1c and increased weight loss more than weekly exenatide ER. Annals of Internal Medicine. 168(8), JC46.
Bekiari, E., Karagiannis T., & Tsapas A. (2018).  In type 2 diabetes, weekly semaglutide reduced HbA1c and increased weight loss more than weekly exenatide ER.. Ann Intern Med. 168(8), JC46.
Bistola, V., Lambadiari V., Dimitriadis G., Ioannidis I., Makrilakis K., Tentolouris N., et al. (2018).  Possible mechanisms of direct cardiovascular impact of GLP-1 agonists and DPP4 inhibitors. Heart Failure Reviews. 377 - 388.
Bistola, V., Lambadiari V., Dimitriadis G., Ioannidis I., Makrilakis K., Tentolouris N., et al. (2018).  Possible mechanisms of direct cardiovascular impact of GLP-1 agonists and DPP4 inhibitors.. Heart Fail Rev. 23(3), 377-388.
Bougioukas, K. I., Liakos A., Tsapas A., Ntzani E., & Haidich A-B. (2018).  Preferred reporting items for overviews of systematic reviews including harms checklist: a pilot tool to be used for balanced reporting of benefits and harms. Journal of Clinical Epidemiology. 93, 9 - 24.
Bougioukas, K. I., Liakos A., Tsapas A., Ntzani E., & Haidich A-B. (2018).  Preferred reporting items for overviews of systematic reviews including harms checklist: a pilot tool to be used for balanced reporting of benefits and harms.. J Clin Epidemiol. 93, 9-24.
Andreadis, P., Karagiannis T., Malandris K., Avgerinos I., Liakos A., Manolopoulos A., et al. (2018).  Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis.. Diabetes Obes Metab. 20(9), 2255-2263.
Andreadis, P., Karagiannis T., Malandris K., Avgerinos I., Liakos A., Manolopoulos A., et al. (2018).  Semaglutide for type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes, Obesity and Metabolism.
Vlachaki, E., Gavriilaki E., Kafantari K., Adamidou D., Tsitsikas D., Chasapopoulou E., et al. (2018).  Successful Outcome of Hyperhemolysis in Sickle Cell Disease following Multiple Lines of Treatment: The Role of Complement Inhibition.. Hemoglobin. 42(5-6), 339-341.
2017
Mainou, M., Madenidou A-V., Liakos A., Paschos P., Karagiannis T., Bekiari E., et al. (2017).  Association between response rates and survival outcomes in patients with newly diagnosed multiple myeloma. A systematic review and meta-regression analysis.. Eur J Haematol. 98(6), 563-568.
Mainou, M., Madenidou A-V., Liakos A., Paschos P., Karagiannis T., Bekiari E., et al. (2017).  Association between response rates and survival outcomes in patients with newly diagnosed multiple myeloma. A systematic review and meta-regression analysis. European Journal of Haematology. 98111125151171328622526459851317339343312102118301141312212432349259292117201512520158233100(6), 563 - 568.
Karagiannis, T., Bekiari E., & Tsapas A. (2017).  Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy.. Core Evid. 12, 1-10.
Karagiannis, T., Bekiari E., & Tsapas A. (2017).  Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy. Core Evidence. Volume 12, 1 - 10.
Katsoula, A., Paschos P., Haidich A-B., Tsapas A., & Giouleme O. (2017).  Diagnostic Accuracy of Fecal Immunochemical Test in Patients at Increased Risk for Colorectal Cancer. JAMA Internal Medicine. 177(8), 1110.
Klonizakis, P., Klaassen R., Sousos N., Liakos A., Tsapas A., & Vlachaki E. (2017).  Evaluation of the Greek TranQol: a novel questionnaire for measuring quality of life in transfusion-dependent thalassemia patients. Annals of Hematology. 9635386959511886953716410511460363056271262012394215457(1111435131343Suppl 21151168618233445), 1937 - 1944.
Klonizakis, P., Klaassen R., Sousos N., Liakos A., Tsapas A., & Vlachaki E. (2017).  Evaluation of the Greek TranQol: a novel questionnaire for measuring quality of life in transfusion-dependent thalassemia patients.. Ann Hematol. 96(11), 1937-1944.
Liakopoulou, P., Liakos A., Vasilakou D., Athanasiadou E., Bekiari E., Kazakos K., et al. (2017).  Fixed ratio combinations of glucagon like peptide 1 receptor agonists with basal insulin: a systematic review and meta-analysis.. Endocrine. 56(3), 485-494.
Liakopoulou, P., Liakos A., Vasilakou D., Athanasiadou E., Bekiari E., Kazakos K., et al. (2017).  Fixed ratio combinations of glucagon like peptide 1 receptor agonists with basal insulin: a systematic review and meta-analysis. Endocrine. 5625815134372239371731583439396341596(31134341111109129114943), 485 - 494.
Bekiari, E., Karagiannis T., Haidich A-B., & Tsapas A. (2017).  Meta-analysis of artificial pancreas trials: methodological considerations. The Lancet Diabetes & Endocrinology. 5(9), 685.
Bekiari, E., Karagiannis T., Haidich A-B., & Tsapas A. (2017).  Meta-analysis of artificial pancreas trials: methodological considerations.. Lancet Diabetes Endocrinol. 5(9), 685.
Stoimenis, D., Karagiannis T., Katsoula A., Athanasiadou E., Kazakos K., Bekiari E., et al. (2017).  Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis.. Expert Opin Pharmacother. 18(9), 843-851.
Stoimenis, D., Karagiannis T., Katsoula A., Athanasiadou E., Kazakos K., Bekiari E., et al. (2017).  Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Expert Opinion on Pharmacotherapy. 18555857646565(9111111), 843 - 851.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές